The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines
Open accessAbstract
Pulmonary administration route has been extensively exploited for the treatment of local lung diseases such as asthma, chronic obstructive pulmonary diseases and respiratory infections, and systemic diseases such as diabetes. Most inhaled medicines could be cleared rapidly from the lungs and their therapeutic effects are transit. The inhaled medicines with extended pulmonary exposure may not only improve the patient compliance by reducing the frequency of drug administration, but also enhance the clinical benefits to the patients with improved therapeutic outcomes. This article systematically reviews the physical and chemical strategies to extend the pulmonary exposure of the inhaled medicines. It starts with an introduction of various physiological and pathophysiological barriers for designing inhaled medicines with extended lung exposure, which is followed by recent advances in various strategies to overcome these barriers. Finally, the applications of the inhaled medicines with extended lung exposure for the treatment of various diseases and the safety concerns associated to various strategies to extend the pulmonary exposure of the inhaled medicines are summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxic potential of materials at the nanolevel
Nel, A., Xia, T., Mädler, L., & Li, N. (2006) · Science · doi:10.1126/science.1114397 · Cited by 9,324
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
The importance of nanoparticle shape in cancer drug delivery
Truong, N. P., Whittaker, M. R., Mak, C. W., & Davis, T. P. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.950564 · Cited by 594
Comparative study of pulmonary responses to nano- and submicron-sized ferric oxide in rats
Zhu, M.-T., Feng, W.-Y., Wang, B., Wang, T.-C., Gu, Y.-Q., Wang, M., Wang, Y., Ouyang, H., Zhao, Y.-L., & Chai, Z.-F. (2008) · Toxicology · doi:10.1016/j.tox.2008.02.011 · Cited by 276
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases
Andrade, F., Rafael, D., Videira, M., Ferreira, D., Sosnik, A., & Sarmento, B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.020 · Cited by 245
Gill, S., Löbenberg, R., Ku, T., Azarmi, S., Roa, W., & Prenner, E. J. (2007) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2007.015 · Cited by 118
Cited by
Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome
Zoulikha, M., Xiao, Q., Boafo, G. F., Sallam, M. A., Chen, Z., & He, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.009 · Cited by 275
Metadata
- Authors
- Guo, Y., Bera, H., Shi, C., Zhang, L., Cun, D., & Yang, M.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 11
- Issue
- 8
- Pages
- 2565-2584
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3163966710
- Cited by
- 169
- References
- 6
- FWCI
- 13.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. https://app.cochat.ai/papers/10.1016/j.apsb.2021.05.015
- The paper
- Guo, Y., Bera, H., Shi, C., Zhang, L., Cun, D., & Yang, M. (2021). Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2021.05.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.